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White-to-beige conversion of adipocytes is one of the most promising approaches to therapeutically target
obesity; however, the signals driving this process had largely remained unclear. Recently, two publications,
Brestoff et al. (2014) in Nature and Lee et al. (2015) in Cell, showed that group 2 innate lymphoid cells directly
regulate adipocyte differentiation and drive the growth of beige fat.Over the last decades, obesity has
become a growing problem in industrial
countries. When it comes to fat tissue,
thermogenic beige adipocytes are consid-
ered more healthy than white adipose tis-
sue, since their heat production leads to
catabolic programs inwhite adipose tissue
(WAT) and overall decreased fat mass. It
had previously been shown that immune
cells and ‘‘beiging’’ of WAT are closely in-
tertwined. Eosinophils present in white ad-
ipose tissue sustain alternatively activated
macrophages (AAMs) (Nguyen et al., 2011;
Wu et al., 2011). In response to eosinophil-
derived IL-4, AAMs produce norepineph-
rine, which stimulates beige adipocytes
and leads to a beneficial caloric balance
(Qiu et al., 2014).
Group 2 innate lymphoid cells (ILC2)
react to IL-33 stimulation with the produc-
tion of copious amounts of the type 2 cy-
tokines IL-5 and IL-13. They were initially
identified in fat-associated lymphoid clus-
ters (Moro et al., 2010) and were recently
shown to be critical for recruitment and
maintenance ofWAT-resident eosinophils
(Molofsky et al., 2013). However, it had re-
mained unclear whether ILC2 contribute
to the beiging of WAT only via the eosino-
phil axis or whether they would have
eosinophil-independent functions. Two
recent publications have now elegantly
addressed the mechanisms by which
ILC2 might contribute to the generation
of beige adipocytes (Brestoff et al.,
2014; Lee et al., 2015). Both reports
show that administration of the ILC2 stim-
ulant IL-33 resulted in increased numbers
of ILC2 in WAT, concurrent with an in-
crease in beige fat cells and oxygen con-
sumption. In contrast, IL-33 administra-
tion had no effect on brown adipose
tissue. Artis and colleagues further re-
ported that IL-33-deficient animals gained152 Cell Metabolism 21, February 3, 2015 ª2more weight than controls and showed
increased WAT (Brestoff et al., 2014). At
the same time, ILC2 and beige adipocyte
numbers were reduced in WAT of Il33/
animals. Intriguingly, reconstituting alym-
phoid mice (i.e., Rag2/ Il2rg/) with
ILC2 alone was sufficient to promote
beiging of WAT, demonstrating a central
role for IL-33 and ILC2 in the regulation
of adipose tissue growth.
Taking a closer look at adipocytes,
Chawla and colleagues observed in-
creased proliferation of adipocyte pro-
genitors after IL-33 administration and
both adipocyte progenitor numbers and
proliferation were reduced in the absence
of IL-4 signaling (Lee et al., 2015). Surpris-
ingly, tissue-specific deletion of IL-4Ra
showed that IL-4 acted directly on adipo-
cyte progenitors, bypassing the AAM-
norepinephrine axis. As a result of stimu-
lation with IL-4, adipocyte progenitors
upregulated genes associated with differ-
entiation of beige adipocytes, such as
Ucp1, Klhl13, Tnfrsf9, and Tmem26. In
contrast, IL-4Ra signaling was dispens-
able in differentiated adipocytes. Intrigu-
ingly, IL-4Ra does not only convey IL-4
signaling, but also binds IL-13, and both
IL-4 and IL-13 led to proliferation of adipo-
cyte progenitors upon administration
in vivo. Even in the absence of IL-4-pro-
ducing eosinophils, the authors detected
substantial proliferation of adipocyte pro-
genitors, suggesting that ILC2-derived
IL-13 might act directly on adipocyte pro-
genitors and could function synergisti-
cally with eosinophil-derived IL-4 to
promote beige adipocyte development.
However, the relative contribution of IL-4
and IL-13 remains to be shown.
In order to determine how ILC2
contribute to beiging of WAT, Brestoff
et al. compared obesity-associated genes015 Elsevier Inc.expressed by ILC2, but not ILC3 (Brestoff
et al., 2014). They discovered that propro-
tein convertase subtilisin/kexin type 1
(Pcsk1) as well as its target proenkephalin
A (Penk) were highly expressed in ILC2.
One product of Penk processing is the
peptide methionine-enkephalin (MetEnk),
of which the authors subsequently
showed that it was produced by ILC2
and increased after IL-33 stimulation.
Treatmentof animalswithMetEnk resulted
in an increase of the beige adipocyte
marker UCP1 in WAT as well as elevated
oxygen consumption. Intriguingly, this
phenotype is very likely independent of
IL-4 and IL-13, since neither cytokine
expression was changed upon MetEnk
administration. However, Artis and col-
leagues found that one of the receptors
for MetEnk, d1 opioid receptor (Oprd1),
was highly expressed in inguinal WAT
(Brestoff et al., 2014). These data suggest
that ILC2 can directly promote conversion
ofWAT into beige adipocytes by secreting
MetEnk, which is sensed by d1 opioid re-
ceptor on WAT and induces genes that
promote beiging. However, studies using
Oprd1 mutant animals will be needed to
determine the role of MetEnk production
by ILC2 in WAT beiging.
While ILC2 were known to be present in
mouseWAT, it had been less clearwhether
this would be applicable to humans. Brest-
off et al. showed that ILC2constitute a sub-
stantial fraction of lineage marker negative
cells in adipose tissue of lean human do-
nors (Brestoff et al., 2014). Interestingly,
fat tissue from obese patients as well as
frommice fedwith a high fat diet contained
substantially fewer ILC2, although IL-33
expression is increased in adipose tissue
of obese humans (Zeyda et al., 2013).
One possible explanation for these contra-
dictory findingsmight be that IL-33 sensing
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Figure 1. ILC2 Play a Central Role in Beiging of White Adipose
Tissue
ILC2 can regulate beiging of adipose tissue in multiple ways after being trig-
gered by IL-33. On the one hand, they produce the type 2 cytokine IL-5, which
in turn activates eosinophils and triggers IL-4 production. In response to IL-4,
alternatively activated macrophages produce norepinephrine that results in
beiging of adipose tissue. New data by Lee et al. demonstrate that eosino-
phil-derived IL-4 as well as ILC2-derived IL-13 (receptor complexes of both
cytokines share the IL-4Ra chain) directly act on adipocyte progenitors, stim-
ulate their proliferation, and promote their differentiation toward beige adipo-
cytes (Lee et al., 2015). Additionally, ILC2 produce the peptide MetEnk, which
can directly bind to the d1 opioid receptor expressed on white adipose tissue
and thereby promote the generation of beige adipocytes (Brestoff et al., 2014).
However, it remains to be shown whether both pathways exist in parallel and
which cells are targeted by MetEnk. While white adipocytes were shown to
produce IL-33, it is not clear whether they are the physiologically relevant
source of this ILC2 activator. Pathways discovered in the featured articles
are shown in bold.
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Taken together, an exciting
insight into the role of innate
immune system components
(i.e., ILC2) in lipid metabolism
is emerging. Although both re-
ports identifieddifferentmecha-
nismsas tohow ILC2control the
beiging of WAT, it is well
conceivable that these path-
ways synergize in the gener-
ation of beige adipocytes
(Figure 1). Although it had previ-
ously been shown that eosino-
phils and AAM contribute to
beiging, the groups of Artis
and Chawla now demonstrate
that ILC2 can directly regulate
adipocyte development and
differentiation, thus rendering
them a promising target for
future treatment of obesity.
While both studies are largely
promoting the same view,
there are some small differ-
ences that need to be clarified
in the future. In contrast to
Lee et al., Artis and colleagues
observed that administration
of IL-33 to Il4ra/ animals re-
sulted in increased numbers
of UCP1+ adipocytes, sug-
gesting a direct role of IL-33 in-
dependent of IL-4 signaling.
Several lines of inquiry will
need to be pursued to betterunderstand how ILC2 act on adipocytes.
For example, it will be interesting to deter-
mine the relative contribution of IL-4, IL-
13, and MetEnk to the beiging of WAT.
From the above discussed publications,
it remained unclear as to whether both
pathways act on the same cells or
whether there are multiple layers of regu-
lation for the beiging of fat. Human
white adipose tissue adipocytes wereshown to produce IL-33, which can be
increased by treatment with pro-inflam-
matory stimuli such as TNF (Wood et al.,
2009). However, it remains to be shown
whether adipocytes themselves are the
main source of IL-33 and how ILC2 affect
this endogenous feedback mechanism.
Lastly, it will be exciting to find how these
pathways can be employed in order to
increase IL-33 levels in vivo and paveCell Metabolism 21, February 3,new roads on the way to
novel treatments of obesity.
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